A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Trial Profile

A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary) ; Hydroxycarbamide
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms PROUD-PV
  • Sponsors AOP Orphan Pharmaceuticals AG
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 According to an AOP Orphan Pharmaceuticals AG media release, latest results from the study were presented at the 22nd Congress of the European Hematology Association (EHA) 2017.
    • 25 Jun 2017 Results published in an AOP Orphan Pharmaceuticals AG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top